Last updated: February 21, 2026
What is NDC 00113-8100?
NDC 00113-8100 refers to a specific drug product listed in the FDA’s National Drug Code registry. According to available data, this code is associated with Cetuximab (Erbitux), a monoclonal antibody used for treating metastatic colorectal cancer and head and neck squamous cell carcinoma.
Market Size and Demand Dynamics
Current Market Scope
The global cetuximab market was valued at approximately USD 2.4 billion as of 2022. The primary markets are North America, Europe, and Asia-Pacific, which collectively account for over 75% of sales.
Usage and Clinical Context
- Indications: Colorectal cancer, head/night neck squamous cell carcinoma.
- Patient Population: Estimated at 120,000 new cases annually in the U.S. and similar figures globally.
- Administration: Intravenous infusion, typically administered weekly or biweekly.
Market Drivers
- Increasing incidences of colorectal and head/neck cancers.
- Expanding treatment guidelines favoring targeted therapies.
- Growing adoption in combination therapy regimens.
Market Limiters
- Biosimilar competition.
- Pricing pressures due to health payers.
- Stringent regulatory requirements for biosimilar approvals.
Competitive Landscape
Top Players
| Company |
Market Share |
Product Name |
Year of Launch |
Key Differentiators |
| Merck KGaA (Eli Lilly partner) |
~45% |
Erbitux |
2004 |
Established brand, global presence |
| Biosimilar Manufacturers |
~35% |
Various biosimilars |
2019–2022 |
Reduced pricing, patent expirations |
| Other Innovators |
20% |
N/A |
N/A |
Entry of new biosimilars, pipeline drugs |
Biosimilar Trends
Biosimilar versions of cetuximab have entered markets starting 2019, notably in Europe and Asia, reducing market share and pricing power for originator products.
Price Trends and Projections
Current Retail and Wholesale Prices
- U.S. Wholesale Acquisition Cost (WAC): Approx. USD 3,500–4,000 per vial (100 mg).
- Average Patient Dose: 400 mg initially, followed by 250 mg weekly.
- Treatment Course Cost: Approx. USD 40,000–50,000 per patient.
Price Drivers
- Biosimilar entry has led to price reductions of 15–30% over 3 years.
- Payers' incentives to switch to biosimilars have further lowered prices.
- Variable pricing based on country rebates, negotiated discounts, and healthcare policies.
Future Price Projections (Next 5 Years)
| Year |
Estimated Price Range (USD per vial) |
Key Factors |
| 2023 |
3,200 – 3,800 |
Market stabilization |
| 2024 |
3,000 – 3,600 |
Increased biosimilar competition |
| 2025 |
2,800 – 3,400 |
Price erosion continues |
| 2026 |
2,600 – 3,200 |
Greater biosimilar penetration |
| 2027 |
2,400 – 3,000 |
Market saturation |
Revenue Impact Estimates
Assuming annual treatment of 100,000 patients in the U.S., revenue could drop from approximately USD 4 billion in 2022 to around USD 2.5 billion by 2027, primarily due to biosimilar pricing and volume shifts.
Regulatory and Policy Factors
- Biosimilar approvals in the U.S. since 2019 (e.g., Amgen’s Kanjinti biosimilar) influence pricing.
- Reimbursement policies favor biosimilar uptake, pressuring originator prices.
- Patent litigation and exclusivity periods determine market longevity.
Key Market Opportunities and Risks
Opportunities
- Growing use in combination regimens expanding market size.
- Developing markets with increasing cancer prevalence.
- Potential for new indications or enhanced formulations.
Risks
- Biosimilar and generic competition.
- Pricing controls and reimbursement restrictions.
- Clinical preference shifts to other therapies.
Summary
NDC 00113-8100, associated with cetuximab (Erbitux), is facing declining prices driven by biosimilar market entry, with a projected decrease of up to 25–30% over the next five years. Market growth remains supported by increasing cancer incidences; however, intense competition and policy dynamics could limit revenue expansion.
Key Takeaways
- The current retail cost per vial in the U.S. is approximately USD 3,200–3,800.
- Biosimilar competition has exerted downward pricing pressure since 2019.
- Market value in global terms is approximately USD 2.4 billion as of 2022.
- Revenues are expected to decline by roughly 35% over the next five years.
- Emerging markets and combination therapy opportunities offer growth potential amidst price erosion.
FAQs
What are the main factors influencing cetuximab prices today?
Market competition, biosimilar entries, healthcare policies, and negotiated discounts shape pricing. Dose regimens and treatment durations also affect overall costs.
How soon will biosimilar competition impact prices significantly?
Most biosimilars entered the market post-2019, with observable price reductions over three years. Continued biosimilar proliferation will further influence prices over the next two to three years.
Are there new indications or formulations likely to affect the market?
Research into new combinations and formulations (e.g., subcutaneous versions) could extend patent life or create market niches, but currently, no major changes are imminent.
What is the outlook for manufacturers relying on Erbitux?
The original manufacturer must contend with biosimilar competition and downward pricing trends, emphasizing the need for diversification or innovation.
How does the U.S. price compare to international markets?
U.S. prices are generally higher than Europe and Asia, due to different healthcare reimbursement structures. Biosimilar adoption is also more advanced in these regions, leading to variations in market dynamics.
References
[1] MarketWatch. (2023). "Global Cetuximab Market Size, Share & Trends Analysis." MarketWatch.
[2] EvaluatePharma. (2022). "Oncology Market Trends."
[3] FDA. (2021). "Biosimilar Product Information."
[4] IQVIA. (2022). Market Dynamics Report.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policy Updates.
